Introduction: Assessment of H. pylori infection and related alteration of serum gastrin levels with the risk of hepatocellular carcinoma in HCV-related liver cirrhosis is still debated. Aims: Our study aims to assess H. Pylori status in HCV-related liver cirrhosis and to find out its impact on the development of HCC in these patients from our community. Patients & Methods: The current study included 60 subjects. They were divided into two groups, thirty patients with HCV-related cirrhotic patients with HCC (Case group) Group (1) and thirty patients with HCV-related cirrhotic patients without HCC (Control group) Group (2). Clinical, laboratory, and radiologic assessment between the 2 groups for comparison and detection is there is a role of H. pylori, Gastrin hormone level, or Cag A toxin antigen in pathogenesis or development of HCC in patients with HCV-related cirrhosis. Results: There was a statistically significant increase in gastrin level among H pylori +ve cases compared to –ve cases. With no statistically significant difference between HCC and non-HCC H. pylori +ve cases (P value=0.17). Patients complicated with HCC had a higher frequency of H. pylori seropositivity than patients without HCC (76.7% Vs 60%, respectively), There was an increase in Cag A toxin level among the HCC group compared to the Non-HCC group but it was statistically insignificant (P value= 0.07). Conclusions: H. Pylori infection is common in patients with HCV-related liver cirrhosis with no impact on the development of hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Yousif et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: